DUALOGICS - ORTHOMAB
OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies. The company specializes in producing antibodies using standard production and purification techniques which are available in flexible formats that can be tailored to specific target biology and mechanisms of action.
DUALOGICS - ORTHOMAB
Industry:
Biotechnology Therapeutics
Address:
Durham, North Carolina, United States
Country:
United States
Status:
Active
Similar Organizations
Curionic Biotherapeutics
Curionic Biotherapeutics develops a platform technology designed to discover protein therapeutics.
ERAD Therapeutics
ERAD Therapeutics is a developer of a drug platform designed to create novel biological agents to treat orphan diseases
More informations about "Dualogics - OrthoMab"
Dualogics (OrthoMab) Company Profile 2024: Valuation, Investors ...
Dualogics (OrthoMab) General Information Description. Operator of a bispecific platform dedicated to create improved antibody therapies. The company specializes in producing …See details»
AbCellera Acquires OrthoMab Bispecific Platform to Propel the ...
Aug 20, 2020 VANCOUVER, British Columbia, August 20, 2020 – AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). …See details»
Dualogics Sells Antibody Platform to Canadian Company
Aug 20, 2020 Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.. Under the terms of the asset purchase agreement, AbCellera of Vancouver, British …See details»
AbCellera Acquires OrthoMab Bispecific Platform to Propel the ...
Aug 20, 2020 Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to …See details»
AbCellera acquires Dualogics - OrthoMab - 2020-08-20
Aug 20, 2020 Dualogics - OrthoMab OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies. Acquiring Organization: AbCellera AbCellera is an …See details»
AbCellera acquires OrthoMab bispecific platform from …
Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to complete existing partnership programs. Dr. Tim Jacobs, who …See details»
AbCellera acquires OrthoMab bispecific platform
Aug 25, 2020 Under the terms of the asset purchase agreement, AbCellera acquires full rights to the OrthoMab platform and Dualogics retains rights to develop existing internal assets and to …See details»
Dualogics - OrthoMab - Crunchbase
OrthoMab is an operator of a bispecific platform dedicated to creating improved antibody therapies.See details»
Durham startup Dualogics sells platform for producing …
Aug 20, 2020 The Biotech Center also provided a loan to Dualogics in 2018 for $250,000. Dualogics has subsequently been supported by grants from the National Cancer Institute and UNC’s Kickstart Venture ...See details»
Dualogics Company Profile 2024: Valuation, Funding
Dualogics General Information Description. Operator of a research and development company intended to develop bi-specific antibodies targeting oncology and autoimmune disease. The company's service specializes in …See details»
AbCellera Acquires OrthoMab Bispecific Platform to Propel the ...
Aug 20, 2020 AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics. Dr. Tim Jacobs CTO of Dualogics joins AbCellera’s team.See details»
AbCellera acquires OrthoMab bispecific platform from Dualogics
Aug 25, 2020 AbCellera announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). OrthoMab is a clinically validated platform that uses the most …See details»
AbCellera Acquires OrthoMab Bispecific Platform to Propel the ...
Aug 25, 2020 AbCellera today announced the acquisition of the OrthoMab bispecific platform from Dualogics, LLC. (Dualogics). OrthoMab is a clinically validated platform that uses the …See details»
Dualogics - Products, Competitors, Financials, Employees, …
Aug 21, 2020 Dualogics focuses on advancements in protein engineering to create improved antibody therapies. Use the CB Insights Platform to explore Dualogics's full profile. Dualogics - …See details»
AbCellera buys OrthoMab platform to move into bispecifics
Aug 24, 2020 AbCellera has positioned itself to serve the emerging bispecific market by acquiring OrthoMab from Dualogics, a US biotech. Dualogics applied the platform to projects …See details»
Dualogics - Crunchbase Company Profile & Funding
Dualogics is a biotechnology company housed at the University of North Carolina at Chapel Hill. Dualogics uses a proprietary bispecific antibody technology to create bispecific antibody …See details»
Dualogics LLC | www.inknowvation.com
Dualogics LLC is a biotechnology company working out of the University of North Carolina Chapel Hill, to develop bispecific antibodies for research, diagnostic, and therapeutic applications …See details»
Dualogics - OrthoMab - Products, Competitors, Financials, …
Dualogics focuses on advancements in protein engineering to create improved antibody therapies. On August 20th, 2020, Dualogics' OrthoMab platform was acquired by AbCellera …See details»
Dualogics Company Profile - Office Locations, Competitors, …
See insights on Dualogics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»